Transformation 2.0: The GLP-1 RAs as Psychiatric Medications?

Transformation 2.0: The GLP-1 RAs as Psychiatric Medications?

Publication date: Jul 08, 2025

The effect of glucagon-like peptide-1 and glucose dependent insulinotropic polypeptide receptor agonists on neurogenesis, differentiation and plasticity: potential mechanistically-informed therapeutics in the treatment and prevention of mental disorders. A systematic review in effects of glucagon-like peptide-1 (GLP-1) mono-agonists on functional connectivity: target engagement and rationale for the development in mental disorders. The effect of body mass index on glucagon-like peptide receptor gene expression in the post mortem brain from individuals with mood and psychotic disorders. Binge eating in adults with mood disorders: results from the International Mood Disorders Collaborative Project. A systematic review on the role of glucagon-like peptide-1 receptor agonists on alcohol-related behaviors: potential therapeutic strategy for alcohol use disorder. Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: a systematic review. Glucagon-like peptide-1 receptor agonists and risk for suicidal ideation and behaviors in U. S. older adults with type 2 diabetes: a target trial emulation study.

Concepts Keywords
Bloomgarden Agonists
Canada Al
Pilot Cns
Psychopharmacology Disorder
Disorders
Eg
Glp
Glucagon
Mental
Peptide
Psychiatric
Ras
Receptor
Target
Treatment

Semantics

Type Source Name
drug DRUGBANK Rasagiline
disease MESH mental disorders
drug DRUGBANK Tropicamide
drug DRUGBANK Esketamine
disease MESH depressive disorders
disease MESH anhedonia
pathway REACTOME Release
disease MESH obesity
disease MESH type 2 diabetes mellitus
disease MESH obstructive sleep apnea
disease MESH cardiovascular disease
disease MESH psychotic disorders
disease MESH premature mortality
disease MESH binge eating disorder
disease MESH polycystic ovarian syndrome
disease MESH nonalcoholic steatohepatitis
disease MESH weight gain
pathway REACTOME Metabolism
disease MESH weight loss
pathway REACTOME Apoptosis
pathway REACTOME Long-term potentiation
drug DRUGBANK Ketamine
disease MESH oxidative stress
drug DRUGBANK Nitric Oxide
disease MESH B-cell lymphoma
disease MESH neurocognitive disorders
disease MESH neurofibrillary tangles
disease MESH Alzheimer disease
pathway KEGG Alzheimer disease
disease MESH Parkinson disease
pathway KEGG Parkinson disease
disease MESH major depressive disorder
disease MESH alcohol use disorder
disease MESH mood disorders
disease MESH cognitive dysfunction
drug DRUGBANK Lixisenatide
disease MESH abnormalities
drug DRUGBANK Exenatide
drug DRUGBANK Semaglutide
disease MESH dementia
disease MESH relapse
disease MESH substance use disorder
drug DRUGBANK Rimonabant
disease MESH depression
drug DRUGBANK Clozapine
drug DRUGBANK Olanzapine
drug DRUGBANK Dextrose unspecified form
disease MESH abdominal obesity
disease MESH bipolar disorder
disease MESH schizophrenia
disease MESH liver disease
disease MESH Binge eating
drug DRUGBANK Liraglutide
disease MESH neurodegenerative disorders
disease MESH anxiety
disease MESH diabetes mellitus
drug DRUGBANK Ethanol
drug DRUGBANK Nicotine
disease MESH suicide
disease MESH suicidal ideation
disease MESH death

Original Article

(Visited 2 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *